tetano
Editor, Senior Moderator
Antiviral Res
. 2022 Nov 14;105462.
doi: 10.1016/j.antiviral.2022.105462. Online ahead of print.
Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model
Fan Yang[SUP] 1 [/SUP], Sijing Yan[SUP] 1 [/SUP], Linwei Zhu[SUP] 1 [/SUP], Frederick X C Wang[SUP] 2 [/SUP], Fumin Liu[SUP] 1 [/SUP], Linfang Cheng[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Nanping Wu[SUP] 1 [/SUP], Rufeng Lu[SUP] 3 [/SUP], Haibo Wu[SUP] 4 [/SUP]
Affiliations
Abstract
The influenza A (H1N1) pdm09 virus attracted public attention because of its high prevalence. The annual global morbidity and mortality rates of influenza remain high despite the application of influenza vaccines and antiviral drugs, which indicates the urgent need to identify a more effective strategy for controlling and treating A(H1N1) pdm09 influenza infection. To produce a highly effective therapeutic with broad specificity for A(H1N1) pdm09 influenza viruses, we generated 15 murine monoclonal antibodies (mAbs) via hybridoma technology: 11 mAbs demonstrated 20-100% therapeutic protection in a mouse model of A(H1N1) pdm09 infection at a single dose of 10 mg/kg. A humanised bispecific antibody (Bis-Hu11-1) generated based on the mAbs 3D2 and 3D11, combining the specificities of the two mAbs, was also effective in preventing and treating A(H1N1) pdm09 infection in a mouse model. Bis-Hu11-1 demonstrated hemagglutination inhibition (HI) activity against the escape mutants generated by its parental mAbs that resulted in the obvious reduction in the HI activity of the parental mAbs. In summary, we generated a panel of neutralising mAbs against A(H1N1) pdm09 influenza virus. This study presents a promising method for developing neutralising antibodies that potentially target a series of antigenically diverse influenza viruses.
Keywords: Humanised bispecific antibody; Influenza A(H1N1) pdm09 virus; Influenza virus; Monoclonal antibody; Neutralisation.
. 2022 Nov 14;105462.
doi: 10.1016/j.antiviral.2022.105462. Online ahead of print.
Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model
Fan Yang[SUP] 1 [/SUP], Sijing Yan[SUP] 1 [/SUP], Linwei Zhu[SUP] 1 [/SUP], Frederick X C Wang[SUP] 2 [/SUP], Fumin Liu[SUP] 1 [/SUP], Linfang Cheng[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Nanping Wu[SUP] 1 [/SUP], Rufeng Lu[SUP] 3 [/SUP], Haibo Wu[SUP] 4 [/SUP]
Affiliations
- PMID: 36396024
- DOI: 10.1016/j.antiviral.2022.105462
Abstract
The influenza A (H1N1) pdm09 virus attracted public attention because of its high prevalence. The annual global morbidity and mortality rates of influenza remain high despite the application of influenza vaccines and antiviral drugs, which indicates the urgent need to identify a more effective strategy for controlling and treating A(H1N1) pdm09 influenza infection. To produce a highly effective therapeutic with broad specificity for A(H1N1) pdm09 influenza viruses, we generated 15 murine monoclonal antibodies (mAbs) via hybridoma technology: 11 mAbs demonstrated 20-100% therapeutic protection in a mouse model of A(H1N1) pdm09 infection at a single dose of 10 mg/kg. A humanised bispecific antibody (Bis-Hu11-1) generated based on the mAbs 3D2 and 3D11, combining the specificities of the two mAbs, was also effective in preventing and treating A(H1N1) pdm09 infection in a mouse model. Bis-Hu11-1 demonstrated hemagglutination inhibition (HI) activity against the escape mutants generated by its parental mAbs that resulted in the obvious reduction in the HI activity of the parental mAbs. In summary, we generated a panel of neutralising mAbs against A(H1N1) pdm09 influenza virus. This study presents a promising method for developing neutralising antibodies that potentially target a series of antigenically diverse influenza viruses.
Keywords: Humanised bispecific antibody; Influenza A(H1N1) pdm09 virus; Influenza virus; Monoclonal antibody; Neutralisation.